Партнеры 2021

With the support of
Knowledge Partner
Business Programme Partners of the Forum entitled "The Drug Security"
Partner of the Forum entitled ‘The Drug Safety and Security’
General media partner
Media Partners
With the support of

The Forum takes place with the support of the Ministry of Health of the Russian Federation and the Subcommittee on Drug Distribution and Development of the Pharmaceutical and Medical Industry of the State Duma Healthcare Committee.

Business Programme Partner of the Forum entitled "The Drug Security"

Sanofi is a leading global healthcare company whose mission is to support people with health challenges. Over 100,000 Sanofi employees in more than 100 countries all over the world take action daily transforming scientific innovations into healthcare solutions.

Sanofi has been present in Russia since the 1970-ies being a leader of a Russian pharmaceutical market for the last 6 years2 and offering our patients a broad portfolio of original medicines and OTC drugs in key therapeutic areas (diabetes, cardiovascular disorders, oncology, rare diseases and multiple sclerosis, immunology), as well as vaccines.

Strategy of Sanofi in Russia corresponds with main healthcare priorities of the state: localization of products for treatment of socially significant diseases not only increased accessibility of innovative therapy for Russian patients, but also reinforced export potential of Russia in European Union.

Oxana Monge - General Manager Sanofi Eurasia

Amgen LLC
Business Programme Partner of the Forum entitled "The Drug Security"

Amgen is a biotechnology company engaged in the development, production and distribution of innovative drugs created by genetic engineering. Founded in 1980, Amgen Is a leader in the biotechnology industry and one of the first companies to unlock the potential of a new generation of effective and safe drugs and fundamentally new approaches to the treatment of serious diseases.

 Amgen drugs have changed everyday medical practice, helping millions of people around the world to deal with severe oncological, hematological and nephrological diseases, rheumatoid arthritis and other serious pathologies. The extensive portfolio of drugs being developed to date (more than 50 new molecules at different stages of development and research) confirms the company's commitment to using scientific advances to improve people's lives.

 Like 35 years ago, Amgen remains true to its mission:

"Serve patients suffering from severe diseases by developing innovative medicines to meet medical needs."

Mr. Ugur Gunaydin - The General Director of Amgen Russia & CIS

JSC «GlaxoSmithKline Trading»
Business Programme Partner of the Forum entitled "The Drug Security"

GSK is a science-led global healthcare company with a special purpose – to help people do more, feel better, live longer. Being headquartered in the UK GSK operates in more than 150 countries and has 3 global businesses that discover, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. Around 100 000 employees work for GSK around the world with more than 16,000 people working in R&D.

 More than 100 GSK prescription drugs are registered in Russia, which are used for the treatment of respiratory diseases, infectious diseases, including HIV infection, diseases of the central nervous system, as well as in the field of urology, immunology, rheumatology, dermatology and in vaccine procurement. GSK is one of the industry leaders in terms of investment in R&D in Russia.

Sean Reilly - VP & General Manager

JSC «Pharmasyntez»
Business Programme Partner of the Forum entitled "The Drug Security"

Pharmasyntez is the largest national manufacturer of drugs for the treatment of socially significant diseases, such as oncology, diabetes mellitus, infectious diseases. Its production facilities are represented by five modern high-tech plants in the following cities: Ussuriysk, Irkutsk, Bratsk, Tyumen, and Saint Petersburg. The company's product portfolio comprises over 180 drug products in various dosage forms: capsules, tablets, granules, tubes, suppositories, prefilled syringes, cartridges, ampules, vials. More than 80% of the drugs produced are included in the list of vital and essential drugs. The annual production volume is more than 76 mln packages. At the end of 2020, the revenue amounted to 510 mln USD. Pharmasyntez is ranked in the Top Ten manufacturers for the hospital procurement volume (DSM Group: hospital procurement rating, 2020) and in the Top Five manufacturers for the hospital procurement value (ALPHARM: rating of pharmaceutical companies in the state segment, 2020).

Vikram Punia - President Pharmasyntez Group of Companies

Association of Pharmaceutical Manufacturers of the Eurasian Economic Union
Partners of the Forum entitled ‘The Drug Safety and Security’

The Association of Pharmaceutical Manufacturers of the Eurasian Economic Union was registered in 2012.

The purpose of the Association is to create conditions for the pharmaceutical market development in the Russian Federation and other EAEU countries, along with strengthening the position and competitiveness of the domestic pharmaceutical industry.

Members of the Association have main resource centres, including R&D laboratories and production facilities, located in the Russian Federation and other EAEU countries, as well as their own know-how and other intellectual property in the field of development and production of medicines and medical technologies. Among the members of the Association are leading full-cycle pharmaceutical companies, such as “Active Component” JSC, “Biocad” CJSC, “Generium” JSC, OOO “GEROPHARM”, “Nanolek” LLC, “NPO Petrovax Pharm” LLC, “Polysan” LTD, “Pharmstandard” JSC, and HTC “ChemRar”.

STANISLAV ALEKSANDROVICH NAUMOV - Chairman of the Board of the EAEU Association of Pharmaceutical Manufacturers. Professor at the Higher School of Economics. Member of the Presidium of the EAEU Business Council.

“AstraZeneca Pharmaceuticals” LLC
Partners of the Forum entitled ‘The Drug Safety and Security’

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Irina Panarina - General Manager AstraZeneca Russia and Eurasia

Teva Pharmaceutical Industries Ltd
Partners of the Forum entitled ‘The Drug Safety and Security’

Teva Around the World

Teva Pharmaceutical Industries Ltd. is one of the world’s pharmaceutical leaders. Headquartered in Israel, Teva delivers high-quality solutions used by approximately 200 million patients who need treatment in 60 markets every day.

Teva is a global leading generic medicines producer, with a portfolio of over 1,800 molecules that help to produce a wide range of generic products for almost every kind of treatment.

 Teva in Russia

Opening opportunities for affordable health – that’s Teva’s purpose. Over 25 years Teva has been opening up opportunities that afford people access to quality medicines, advanced solutions and the information they need to manage their health. Teva began operating in Russia in 1995 and today it is one of the largest pharmaceutical companies in the Russian market with a portfolio of over 300 products.

Erick Roche - SVP Cluster Head Teva Russia, Eurasia, Turkey and MEA General Manager Teva Russia

Bristol-Myers Squibb
Partners of the Forum entitled ‘The Drug Safety and Security’

Bristol Myers Squibb is the company of breakthroughs – the kind that transform patients` lives. Dedicated to our mission of discovering, developing and delivering life-saving innovations that help patients prevail over serious diseases, we`ll never give up our search for more hope, for more people, around the world.

We focus on innovations, as we believe in the power of science to address some of the most challenging diseases of our time. We have a history of scientific excellence, transforming patient outcomes in major diseases such as cancer, cardiovascular disease, HIV and HCV. We pioneered a class of medicines that harnesses the power of the immune system to treat cancer.

Generating new ideas and thinking differently are at the heart of everything we do for patients. We are driven by the knowledge that our efforts can make the difference for a patient.

Alisa Dzhangiryants - Director of Market Access & Pricing Department Bristol Myers Squibb

NPO Petrovax Pharm LLC
Partners of the Forum entitled ‘The Drug Safety and Security’

Petrovax is a Russian full-cycle biopharmaceutical company with 25 years of successful experience. It was founded in 1996 by a group of Russian scientists. Since 2014, the company has been a part of the Interros Group.

The product portfolio includes original pharmaceutical products and vaccines, generics and dietary supplements. The company has its own research center and investment program for R&D, and holds more than 20 new molecule and manufacturing process patents. The company's complex for manufacturing of APIs and finished dosage forms is located in the Moscow region and operates in full compliance with the Russian and international GMP standards. Petrovax has over 700 employees.

Petrovax's partners are the world's leading pharmaceutical companies: Pfizer, Abbott, Boehringer Ingelheim, CanSino Biologics Inc. Petrovax is the largest Russian exporter of original medicinal products. The company exports products to the countries of the EAEU, the Middle East and the EU.

In 2020-2021 Petrovax conducted large-scale trials of coronavirus vaccine and original medicines products against COVID-19 in Russia and the EU.

MIKHAIL TSYFEROV - President, Member of the Board of Directors, NPO Petrovax Pharm LLC (part of the Interros Group) Managing Director, Winter Capital Fund Private investor in several healthtech, edutech and fintech projects

Media Partner

RBC is a leading Russian media holding, with leadership positions in news and business media, as well as in domain name registration and hosting. The company’s history counts more than 20 years. RBC employs key media platforms such as the Internet,TV,and press,develops B2B media services,and provides domain registration and hosting services (RU-CENTER Group).

RBC’s aggregate monthly business audience exceeds 34m people (source: TNS data, including overlapping audience). At the same time, Rbc.ru has continually been ranked among top online media in the citation ranking (source: Medialogia data for 2014).

RU-CENTER Group provides services to more than 1 million users, with major Russian companies and leading players on the Internet market among them.

In 2013, RBC’s brand was valued at RUB 10.6bn by Interbrand, an international branding agency, making it 24th out of 40 most valuable Russian brands.